Halozyme Therapeutics (HALO) Research & Development: 2009-2025
Historic Research & Development for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $17.3 million.
- Halozyme Therapeutics' Research & Development fell 6.54% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year decrease of 12.40%. This contributed to the annual value of $79.0 million for FY2024, which is 3.52% up from last year.
- Per Halozyme Therapeutics' latest filing, its Research & Development stood at $17.3 million for Q3 2025, which was down 1.66% from $17.5 million recorded in Q2 2025.
- Halozyme Therapeutics' 5-year Research & Development high stood at $22.6 million for Q4 2022, and its period low was $8.1 million during Q2 2021.
- In the last 3 years, Halozyme Therapeutics' Research & Development had a median value of $18.5 million in 2024 and averaged $18.6 million.
- Per our database at Business Quant, Halozyme Therapeutics' Research & Development skyrocketed by 123.25% in 2022 and then dropped by 22.56% in 2025.
- Quarterly analysis of 5 years shows Halozyme Therapeutics' Research & Development stood at $10.1 million in 2021, then soared by 123.25% to $22.6 million in 2022, then fell by 5.45% to $21.3 million in 2023, then decreased by 4.19% to $20.4 million in 2024, then dropped by 6.54% to $17.3 million in 2025.
- Its Research & Development was $17.3 million in Q3 2025, compared to $17.5 million in Q2 2025 and $14.8 million in Q1 2025.